At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 171 enrolled
Drug / intervention
Gefapixant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Four-Week Multicenter Study Evaluating the Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Subjects With Osteoarthritis of the Knee
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Mar 15, 2012·Updated Jun 27, 2019
In Brief
A Phase 2 clinical trial evaluating Gefapixant and Sugar Pill for Osteoarthritis of the Knee. Completed, enrolled 171 participants across 34 sites.
Detailed Summary
The purpose of this study is to assess the efficacy of a single dose level of gefapixant (AF-219/MK-7264) in subjects with moderate to severe pain associated with osteoarthritis (OA) of the knee compared with placebo after 4 weeks of treatment. The study will also assess the safety and tolerability, changes in physical function, stiffness, treatment response and health outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 2012
Enrollment StartMar 2012
Primary CompletionNov 2013
Study CompletionNov 2013
TodayJul 2026
First PostedMar 15, 2012
Enrollment StartMar 29, 2012
Primary CompletionNov 11, 2013
Study CompletionNov 21, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.3 years ago
Interventions
Gefapixantdrug
BID
Sugar Pilldrug
Placebo